Introduction
============

Approximately 30% of patients with cirrhosis have oesophageal varices at the time of diagnosis; this proportion increases with time and reaches 90% after \~10 years ([@b1-etm-0-0-8633]). Patients with oesophageal varices have a high tendency to develop bleeding. Only 10-20% of variceal bleeding occurs from gastric varices, but the associated outcome is worse than that of bleeding from oesophageal varices ([@b2-etm-0-0-8633]). Patients surviving a variceal bleed are at high risk of rebleeding (\>60% in the first year) and the mortality of each rebleeding episode is \~20% ([@b6-etm-0-0-8633]). Therefore, prevention of recurrent variceal bleeding is important for patients with cirrhosis.

For secondary prophylaxis of variceal bleeding, the goal of improving outcomes is evolving, since therapy in these cases attempts to reduce the risk of death, and thus prevent the onset of complications of cirrhosis that may lead to death ([@b1-etm-0-0-8633]). The treatment effectiveness of secondary preventions, including endoscopic ligation or endoscopic sclerotherapy (ES), drug therapies \[non-selective β-blockers (NSBB) with or without isosorbide mononitrate (ISMN)\] and transjugular intrahepatic portosystemic shunts (TIPS) is an area of interest, but at present, a firm consensus as to the most effective treatment has not been reached. Several randomized controlled trials (RCTs) have investigated treatment outcomes in terms of mortality, complications and adverse effects ([@b7-etm-0-0-8633]). A previous study compared endoscopic variceal ligation (EVL) with a combination of EVL and nadolol and identified that adverse effects more frequently occurred in the EVL plus nadolol group (0.03 vs. 33%) ([@b12-etm-0-0-8633]). Another trial compared nadolol plus ISMN alone with EVL plus the drug combination and observed that the combination of EVL and drugs led to more adverse effects (62 vs. 32%), but there were no significant differences in either mortality or the causes of death ([@b11-etm-0-0-8633]). However, a previous direct meta-analysis comprising 925 patients comparing endoscopic therapy with a combination of BB and endoscopic therapy identified that mortality at 24 months was significantly lower in the combined treatment group ([@b13-etm-0-0-8633]). In addition to inconsistent results among the previous trials and analyses, to the best of our knowledge, there has been no previous network meta-analysis to compare treatment outcomes. Therefore, the present study was performed to compare the effectiveness of standard treatments for the secondary prevention of variceal bleeding in patients with cirrhosis through a network meta-analysis. The specific treatments studied were TIPS, endoscopic therapy (EVL alone or ES alone), a combination of EVL and ES, a combination of EVL/ES and NSBB (propranolol and nadolol) with or without ISMN, as well as a combination of NSBB and ISMN.

Materials and methods
=====================

### Literature search

Searches were performed in the electronic PubMed, Cochrane Library, Embase and Web of Science databases in February 2018. The following search terms were used: 'Cirrhotic patients', 'patients with cirrhosis', 'liver cirrhosis', 'haemorrhage', 'bleeding', 'rebleeding', 'variceal', 'oesophageal varices', 'endoscopic variceal ligation', 'endoscopic band ligation', 'endoscopic ligation', 'endoscopic sclerotherapy', 'sclerotherapy', 'endoscopic therapy', 'vasoconstrictors', 'venodilators', 'adrenergic beta antagonist', 'adrenergic-beta antagonist', 'adrenergic beta-antagonist', 'adrenergic-beta-antagonist', 'nitrate', 'beta-blocker', 'isosorbide mononitrate', 'placebo', 'TIPS', 'transjugular intrahepatic portosystemic shunt' and 'randomized controlled trial'. Manual searches of reference lists of relevant articles were also performed to identify additional studies. Only RCTs were included.

### Inclusion and exclusion criteria

RCTs, irrespective of publication status, were included if they investigated endoscopic therapy with various combinations of NSBB and ISMN, or TIPS alone among adult patients with cirrhosis, who had at least one previous episode of upper gastrointestinal bleeding. Trials fulfilling the following criteria were excluded: i) Focus on primary prevention of variceal bleeding; ii) inclusion of pediatric patients or patients without cirrhosis; iii) comparison of only one of the aforementioned treatment regimens with other treatment(s), as it was impossible to make a network comparison; or iv) a clearly irrelevant topic, e.g. nutrition after variceal bleeding.

### Study selection

Only RCTs whose reports were available in English or Chinese were included. If a trial was designed with more than two treatment arms, at least two of the arms had to match the scope of the present study.

### Data extraction

According to the newly published guidelines of the American Association for the Study of Liver Diseases (AASLD) and consensus ([@b14-etm-0-0-8633]), therapies for secondary prophylaxis must account for the presence or absence of other complications of cirrhosis. In patients with a low risk of death (those with variceal haemorrhage as the sole complication of cirrhosis), the objective of therapy should be the prevention of an additional complication, whereas in patients with a high risk of death (those with variceal haemorrhage and other decompensating events), the objective of therapy should be to improve survival ([@b15-etm-0-0-8633],[@b16-etm-0-0-8633]). Mortality (overall mortality, mortality due to rebleeding and mortality due to liver failure), treatment failure and complications (bleeding from gastroesophageal ulcer) were analyzed.

Data of treatment failure were analyzed when clearly stated in the literature, with exclusion of data that satisfied certain criteria but lacked declaration of treatment failure. Authors of the included trials were not approached for further data due to the large number of RCTs selected and acquisition of adequate data associated with treatment outcomes. The primary outcomes were overall mortality, mortality due to rebleeding, including but not limited to recurrent variceal bleeding and mortality due to liver failure. Overall mortality was defined as death that occurred during the trial treatment or follow-up caused by disease progression or treatment complications. Secondary outcomes were treatment failure and bleeding from gastroesophageal ulcers, including but not limited to post-banding ulcers.

### Methodological quality

A bias assessment was performed for the included trials by evaluating randomization, completion of trials and blinding. The major targets were concealment randomization, participant blinding, health care provider blinding, data collector blinding, outcome assessor blinding and early trial cessation.

Randomization was considered concealed if it involved a third independent party or person not involved in the treatment of patients, opaque sealed envelopes or a similar method. Trials were not considered to feature early cessation unless premature termination was specifically announced in the article.

### Statistical analysis

The odds ratio (OR) was used to denote the results with a 95% CI, indicating the strength of association between treatments and outcomes. An OR\<1 represents the benefit of the comparison group compared with the control group. Pooled ORs and their 95% CIs were also calculated. Statistical significance was established with a two-sided P\<0.05 or a CI that did not include a value of 1. The risk ratio was not used to measure outcomes due to limited data regarding the number of events among the selected trials.

To assess the comparability of the included trials, a heterogeneity analysis was performed. Since inconsistency is a source of heterogeneity in network meta-analyses, a generalized Cochran\'s Q statistic (Q^total^) and I^2^ statistic were adopted for assessment of homogeneity and consistency assumptions. Statistical heterogeneity was considered significant when P\<0.10 for the Q-test or I^2^\<50%. The network meta-analysis used fixed-effects models with I^2^ values of 0% for overall mortality, mortality due to rebleeding, mortality due to liver failure and bleeding from a gastroesophageal ulcer, and I^2^=29.4% for treatment failure.

All treatments were ranked according to P-score, which is on a scale from 0 (worst) to 1 (best). P-scores are based solely on the point estimates and standard errors of the most frequent network meta-analysis estimates under normality assumption, and can easily be calculated as means of one-sided P-values. They measure the extent of certainty that a treatment is better than another treatment, averaged over all competing treatments ([@b17-etm-0-0-8633]). Sensitivity analysis was performed by removal of trials with a mean follow-up of \<6 months. The network meta-analyses were performed using R 3.3.1 along with the 'netmeta' package by Schwarzer *et al* ([@b18-etm-0-0-8633]).

Results
=======

### Search results

Electronic and manual searches identified 1,293 records in total. Following screening of titles and abstracts, 861 references were excluded and the remainder was subjected to full-text screening. Among the excluded studies were duplicates, non-RCTs, trials investigating other treatments, or those covering different topics or focusing on primary prevention of variceal bleeding, due to inadequate data for the present study or randomizing patients without cirrhosis. A previous trial investigating the effects of carvedilol plus EVL was excluded, as it assessed hemodynamic responses but not mortality ([@b19-etm-0-0-8633]). The screening process followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and is depicted in a flow chart in [Fig. 1](#f1-etm-0-0-8633){ref-type="fig"}.

### Characteristics of the studies included

A total of 43 trials ([@b20-etm-0-0-8633]) with a total sample size of 3,787 patients with cirrhosis were included for quantitative network meta-analysis. In total, 5 references were published or available as abstracts ([@b22-etm-0-0-8633],[@b35-etm-0-0-8633],[@b39-etm-0-0-8633],[@b42-etm-0-0-8633],[@b43-etm-0-0-8633]) and the remainder were available in full text. A previous trial had 4 treatment arms ([@b44-etm-0-0-8633]), among which 3 (EVL alone, EVL plus propranolol plus ISMN and propranolol plus ISMN) were included from the present study. Another had 3 arms ([@b22-etm-0-0-8633]), of which 2 (EVL alone and propranolol plus ISMN) were included, and the arm of carvedilol treatment alone was excluded. All of the other trials were designed with 2 treatment arms. The proportion of patients with cirrhosis was 100% in all of the trials. The baseline characteristics of the trials are presented in [Table I](#tI-etm-0-0-8633){ref-type="table"}. Patient inclusion and exclusion criteria varied slightly across trials, but patients were generally eligible if they were adults with cirrhosis with at least one episode of endoscopic-proven oesophageal or gastric variceal bleeding. Exclusion criteria included hepatocarcinoma, non-bleeding varices, existing multi-organ failure and lack of cirrhosis. A total of 30 of the 43 studies had a mean follow-up time of \>2 years, as presented in [Table I](#tI-etm-0-0-8633){ref-type="table"}. In total, five trials were excluded from the sensitivity analysis due to follow-up times that were unknown or \<6 months ([@b43-etm-0-0-8633],[@b47-etm-0-0-8633],[@b55-etm-0-0-8633],[@b60-etm-0-0-8633],[@b61-etm-0-0-8633]). TIPS alone was used as the comparative treatment in the forest plots, since it is a recommended surgery for secondary prophylaxis according to the newest UK guidelines ([@b5-etm-0-0-8633]).

### Bias assessment

Risk of bias assessment for the RCTs included was performed following the PRISMA recommendations; the results are presented in [Table SI](#SD2-etm-0-0-8633){ref-type="supplementary-material"}. A total of 26 (61%) trials ([@b20-etm-0-0-8633],[@b24-etm-0-0-8633],[@b34-etm-0-0-8633],[@b36-etm-0-0-8633],[@b38-etm-0-0-8633],[@b44-etm-0-0-8633],[@b47-etm-0-0-8633],[@b16-etm-0-0-8633],[@b50-etm-0-0-8633],[@b56-etm-0-0-8633],[@b61-etm-0-0-8633]) adopted concealed randomization via sealed opaque envelopes, by using central randomization or through an independent person not involved in the treatment of the patients. Only one trial declared early cessation ([@b54-etm-0-0-8633]). A total of two trials were open labelled ([@b20-etm-0-0-8633],[@b24-etm-0-0-8633]) and two trials reported using outcome assessors under blinded conditions ([@b27-etm-0-0-8633],[@b16-etm-0-0-8633]). Blinding of the remaining trials was not specified.

### Overall mortality

In total, 40 trials with a total of 3,599 patients reported overall mortality, involving all 11 treatment regimens. [Fig. S1A](#SD1-etm-0-0-8633){ref-type="supplementary-material"} illustrates the evidence networks connecting the regimens. Nadolol plus ISMN also had the highest P-score (P-score=0.8162, [Table II](#tII-etm-0-0-8633){ref-type="table"}) with the largest probability to reduce mortality when compared with the other treatments. No statistical heterogeneity was observed (Heterogeneity I^2^=0%; Cochran\'s test P=0.9618, [Table III](#tIII-etm-0-0-8633){ref-type="table"}) in this outcome measure. The fixed-effects model analysis suggested that nadolol plus ISMN was significantly more effective than TIPS alone (OR=0.62, 95% CI: 0.40-0.96, [Table III](#tIII-etm-0-0-8633){ref-type="table"}), as presented in [Fig. 2A](#f2-etm-0-0-8633){ref-type="fig"}. Pairwise comparisons indicated that nadolol plus ISMN and EVL alone were significantly more effective than ES alone in reducing overall mortality (OR=0.63, 95% CI: 0.42-0.94; OR=0.80, 95% CI: 0.65-0.99, respectively, [Table III](#tIII-etm-0-0-8633){ref-type="table"}), while differences among other treatments were not statistically significant.

### Mortality due to rebleeding

A total of 27 trials with 2,447 patients investigated all 11 treatments and reported death due to rebleeding. The evidence network presented in [Fig. S1B](#SD1-etm-0-0-8633){ref-type="supplementary-material"} connects all of the treatments. Cochran\'s Q test did not identify any statistical heterogeneity among the selected trials for this outcome measure (Heterogeneity I^2^=0, P=0.9963, [Table III](#tIII-etm-0-0-8633){ref-type="table"}). Compared with TIPS alone, ES plus propranolol increased the risk of mortality due to rebleeding (OR=10.39, 95% CI: 2.24-48.26, [Fig. 2B](#f2-etm-0-0-8633){ref-type="fig"}; P-score=0.0842; [Table II](#tII-etm-0-0-8633){ref-type="table"}).

Pairwise comparisons indicated that ES plus EVL, EVL alone, EVL combined with nadolol plus ISMN, Nadolol plus ISMN, Propranolol plus ISMN and TIPS alone were significantly more effective than ES alone in reducing mortality due to rebleeding (OR=0.23, 95% CI: 0.08-0.69; OR=0.37, 95% CI: 0.21-0.63; OR=0.18, 95% CI: 0.04-0.70; OR=0.29, 95% CI: 0.12-0.69; OR=0.17, 95% CI: 0.04-0.77; OR=0.12, 95% CI: 0.04-0.35, respectively, [Table III](#tIII-etm-0-0-8633){ref-type="table"}).

### Mortality due to liver failure

A total of 24 trials with 2,258 patients investigating all 11 treatments reported on death due to liver failure. The evidence network presented in [Fig. S1C](#SD1-etm-0-0-8633){ref-type="supplementary-material"} connects all of the treatments. No statistical heterogeneity was observed (Heterogeneity I^2^=0%, P=0.8985; [Table III](#tIII-etm-0-0-8633){ref-type="table"}). The results of the fixed-effects model analysis comparing with TIPS alone indicated that none of the other treatments were superior, though nadolol plus ISMN may be the next best option (OR=0.51, 95% CI: 0.22-1.20, [Fig. 2C](#f2-etm-0-0-8633){ref-type="fig"}; P-score=0.7536; [Table II](#tII-etm-0-0-8633){ref-type="table"}). Furthermore, EVL combined with nadolol plus ISMN had the lowest P-score (P-score=0.2167, [Table II](#tII-etm-0-0-8633){ref-type="table"}), indicating the highest probability to increase mortality due to liver failure. Results of pairwise comparisons indicated no statistically significant differences when comparing with treatments other than TIPS ([Table III](#tIII-etm-0-0-8633){ref-type="table"}).

### Treatment failure

In total, 14 trials with a total of 1,445 patients reported on treatment failure. No data of this outcome were available for the treatment regimen ES plus propranolol. The evidence network in [Fig. S1B](#SD1-etm-0-0-8633){ref-type="supplementary-material"} connects the other 10 treatments for assessment of this outcome. Mild heterogeneity was identified for treatment failure (Heterogeneity I^2^=29.4%, P=0.1739; [Table III](#tIII-etm-0-0-8633){ref-type="table"}). A fixed-effects model analysis was performed for comparing with TIPS alone. Differences were not statistically significant ([Fig. 2D](#f2-etm-0-0-8633){ref-type="fig"}). The evidence network presented in [Fig. S1D](#SD1-etm-0-0-8633){ref-type="supplementary-material"} connects all of the treatments. EVL plus propranolol had the highest efficacy (P-score=0.8071), closely followed by TIPS (P-score=0.7938) and EVL plus nadolol (P-score=0.7932). ES alone ranked last (P-score=0.0199), suggesting that it was most likely to have the highest rate of treatment failure. Rankings are presented in [Table II](#tII-etm-0-0-8633){ref-type="table"}.

Pooled ORs suggested that ES alone was disadvantageous compared with the other 9 treatments with regard to treatment failure (OR=3.72, 95% CI: 1.30-10.67 compared with ES plus EVL; OR=2.13, 95% CI: 1.31-3.45 compared with EVL alone; OR=8.65, 95% CI: 1.77-42.15 compared with EVL plus nadolol; OR=3.69, 95% CI: 1.65-8.27 compared with EVL plus nadolol plus ISMN; OR=9.09, 95% CI: 2.08-39.68 compared with EVL plus propranolol; OR=3.02, 95% CI: 1.22-7.53 compared with EVL plus propranolol plus ISMN; OR=2.78, 95% CI: 1.54-5.02 compared with nadolol plus ISMN; OR=2.54, 95% CI: 1.06-6.12 compared with propranolol plus ISMN; OR=8.24, 95% CI: 2.16-31.40 compared with TIPS alone; [Table III](#tIII-etm-0-0-8633){ref-type="table"}).

### Bleeding from gastroesophageal ulcer

A total of 24 trials with a total of 2,258 patients investigated all 11 treatments and reported death due to bleeding from gastroesophageal ulcer. The evidence network is presented in [Fig. S1E](#SD1-etm-0-0-8633){ref-type="supplementary-material"}. There was no statistically significant heterogeneity for this outcome measure (Heterogeneity I^2^=0, P=0.8354; [Table III](#tIII-etm-0-0-8633){ref-type="table"}). Results of the fixed-effects model analysis performed in comparison with TIPS alone indicated that none of the other 10 treatments were superior, but nadolol plus ISMN appeared to be the best among the compared treatments (OR=0.85, 95% CI: 0.09-8.18, [Fig. 2E](#f2-etm-0-0-8633){ref-type="fig"}; P-score=0.7536, [Table II](#tII-etm-0-0-8633){ref-type="table"}).

Nadolol plus ISMN had the highest P-score (P-score=0.7536), indicating that it had the highest probability of reducing mortality due to rebleeding, followed closely by ES alone (P-score=0.6964) and ES plus propranolol (P-score=0.6651). The lowest P-score was obtained for EVL plus nadolol and ISMN (P-score=0.2167), indicating the lowest probability to reduce bleeding from gastroesophageal ulcer ([Table II](#tII-etm-0-0-8633){ref-type="table"}).

Pairwise comparisons among the treatments indicated that nadolol plus ISMN was associated with a relatively lower risk of causing bleeding from gastroesophageal ulcer when compared with ES alone (OR=0.11, 95% CI: 0.02-0.48), ES plus EVL (OR=0.06, 95% CI=0.00-0.97) or EVL alone (OR=0.12, 95% CI: 0.03-0.56) in [Table III](#tIII-etm-0-0-8633){ref-type="table"}.

### Sensitivity analysis

A sensitivity analysis was performed by removing several studies. The only criterion for removal was a mean follow-up time of \<6 months, based on which 5 trials ([@b43-etm-0-0-8633],[@b47-etm-0-0-8633],[@b55-etm-0-0-8633],[@b60-etm-0-0-8633],[@b61-etm-0-0-8633]) were removed. The results were consistent with those of the primary meta-analysis ([Table IV](#tIV-etm-0-0-8633){ref-type="table"}). Nadolol plus ISMN was still superior to TIPS with regard to overall mortality (OR=0.63, 95% CI: 0.40-0.98, [Fig. 3A](#f3-etm-0-0-8633){ref-type="fig"}; Heterogeneity I^2^=0, P=0.9249, [Table IV](#tIV-etm-0-0-8633){ref-type="table"}), while no significant differences were obtained for treatment failure (OR=2.97, 95% CI: 0.74-11.88, [Fig. 3B](#f3-etm-0-0-8633){ref-type="fig"}; Heterogeneity I^2^=37.3%, P=0.1206, [Table IV](#tIV-etm-0-0-8633){ref-type="table"}).

Discussion
==========

The present network meta-analysis included 43 randomized controlled trials to compare the treatment effectiveness of 11 mainstay secondary prophylaxes in patients with cirrhosis in terms of mortality, treatment failure and bleeding from gastroesophageal ulcers. The results suggested that nadolol plus ISMN was most likely to reduce the risk of overall mortality, mortality due to liver failure and bleeding from gastroesophageal ulcers, and was superior to ES and TIPS alone for reducing overall mortality. ES was inferior to 9 treatments for reducing treatment failure. The combination of endoscopic therapy and NSBB with or without ISMN was not significantly more effective than EVL or the drug combination alone.

The present study included 4 trials that investigated nadolol plus ISMN ([@b26-etm-0-0-8633],[@b36-etm-0-0-8633],[@b51-etm-0-0-8633],[@b57-etm-0-0-8633]) with a total of 250 randomized patients. Nadolol plus ISMN was indicated to be more effective than TIPS alone in reducing overall mortality. The present results are consistent with those of Villanueva *et al* ([@b28-etm-0-0-8633]), which concluded that combination therapy was more effective than endoscopic ligation for the prevention of recurrent bleeding and was associated with lower rates of major complications. As a vasoconstrictor, nadolol is able to reduce portal pressure and blood flow in the porto-collateral system. The vasodilator ISMN has been demonstrated to decrease portal pressure in patients with cirrhosis by reducing intra-hepatic resistance ([@b29-etm-0-0-8633]). Despite adverse drug-associated effects, including hypotension, asthenia and headaches, proper dosage of this combination is most likely to reduce mortality and other complications of bleeding from ulcers.

In the newly published AASLD and UK guidelines, TIPS is recommended as a treatment option when endoscopic and pharmacologic treatments have failed ([@b5-etm-0-0-8633]). In the present study, a total of 16 trials provided data for TIPS in 590 patients with cirrhosis ([@b20-etm-0-0-8633],[@b21-etm-0-0-8633],[@b25-etm-0-0-8633],[@b29-etm-0-0-8633],[@b30-etm-0-0-8633],[@b32-etm-0-0-8633],[@b38-etm-0-0-8633],[@b42-etm-0-0-8633],[@b43-etm-0-0-8633]). The mean follow-up time for TIPS groups was 748.5 days \[data for one trial ([@b43-etm-0-0-8633]) were not available\]. Although TIPS is known to have the potential to increase hepatic encephalopathy ([@b20-etm-0-0-8633],[@b27-etm-0-0-8633]), the present study demonstrated that it may reduce the risk of death due to rebleeding. The trials were contradictory regarding whether TIPS is superior to endoscopic or combination therapies. In one previous trial ([@b26-etm-0-0-8633]), TIPS alone was superior to EVL plus propranolol in the prevention of rebleeding, but this superiority did not result in improved survival. In this previous study ([@b26-etm-0-0-8633]), liver failure, hepatobiliary cancer and sepsis were the predominant causes of death. Clinically, it may be difficult to attribute death to rebleeding or to any one cause. Zheng *et al* ([@b62-etm-0-0-8633]) performed a meta-analysis of 12 RCTs to compare TIPS with endoscopic therapy, and the results suggested that TIPS reduced variceal rebleeding, but was associated with an increased risk of encephalopathy, although no differences in survival were observed. The present study indicated that TIPS was superior to ES alone, ES plus propranolol and EVL alone with a tendency for reduced mortality due to rebleeding. In clinical practice, TIPS has certain advantages in reducing portal pressure and reducing the risk of rebleeding. However, compared with endoscopic treatment, TIPS is more costly and technically more difficult.

Data from 4 previous studies ([@b21-etm-0-0-8633],[@b26-etm-0-0-8633],[@b27-etm-0-0-8633],[@b38-etm-0-0-8633]) that used covered stents in their trials provided similar results among TIPS, EVL, EVL plus propranolol and propranolol plus ISMN in terms of overall mortality, although TIPS appeared to cause less mortality due to rebleeding than EVL plus propranolol ([@b21-etm-0-0-8633]).

Although ES was not recommended by the Baveno VI Consensus Workshop as a first-line treatment ([@b15-etm-0-0-8633]), it is still commonly used in China ([@b61-etm-0-0-8633]). Furthermore, the guidelines of the Chinese Society of Gastroenterology, Chinese Medical Association and Chinese Society of Endoscopy suggest that physicians choose EVL or ES for secondary prophylaxis based on their experience and the patients\' clinical conditions ([@b62-etm-0-0-8633]). Therefore, RCTs on ES were not excluded from the present study.

Results of pooled ORs demonstrated inferiority of ES regarding treatment failure over the other 9 treatments. ES plus propranolol may increase the risk of mortality due to rebleeding. No statistically significant benefit of ES alone or ES plus drugs was identified in the present study. The results of the present study are consistent with those of previous studies ([@b7-etm-0-0-8633],[@b15-etm-0-0-8633]) and support the most recent UK and AASLD guidelines, which do not recommend ES for secondary prevention of variceal bleeding in patients with cirrhosis ([@b5-etm-0-0-8633]).

EVL has been accepted as the preferred endoscopic treatment for the prevention of variceal rebleeding ([@b37-etm-0-0-8633]). Although EVL plus NSBB is now the first-line treatment, a review by Cotoras *et al* ([@b64-etm-0-0-8633]) reported that addition of β-blockers to EVL does not lead to a difference in mortality. In line with this, in the present study, the combination of EVL and NSBB with or without ISMN was not more effective than EVL alone or the drug combination of NSBB and ISMN.

The present study identified a tendency of EVL plus propranolol to increase mortality, which may be attributed to the data that were extracted from the included trials for this outcome measure. In a previous trial whose patients all had grade II-IV portal vein thrombosis (PVT), Luo *et al* ([@b21-etm-0-0-8633]) determined that the ability of EVL plus propranolol to reduce variceal bleeding may be counteracted by deteriorated PVT. Additional evidence from high-quality RCTs is required to address this issue.

The present study has several limitations. Therapy using drugs alone or using drugs other than NSBB or ISMN were beyond the scope of the present study, as regimens of single drugs are now seldom used in clinical practice for secondary prophylaxis. Although the included trials provided a solid foundation based on collected data, more data on serious adverse effects, the frequency and severity of drug-associated adverse effects, procedure-associated complications and consequent hospitalization may be helpful for further comparison. The quality of the present study depends on the RCTs that were included. A total of 4 RCTs focusing on acute variceal bleeding ([@b37-etm-0-0-8633],[@b38-etm-0-0-8633],[@b47-etm-0-0-8633],[@b54-etm-0-0-8633]) were included, as they also assessed the outcomes of rebleeding and overall mortality. The included references were published between 1992 and 2015, which is a long period of time; there may be technical differences in the early stages; however, with the continuous standardization and maturity of operation technology, the differences are gradually narrowing. Therefore, the clinical value of the present results may be limited.

In conclusion, the present network meta-analysis suggested that for prophylaxis of variceal rebleeding in patients with cirrhosis, nadolol plus ISMN may be the preferred choice to decrease mortality and ES may be associated with a relatively higher risk of unfavourable treatment outcomes, particularly treatment failure.
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###### 

Characteristic of randomized controlled trials included in the network meta-analysis.

  First author (year)   Treatment groups       Patients (n)   Mean age (years)   Females (%)   Varices, grade or size, n   Child-Pugh class (A/B/C)   Mean Pugh score   Mean follow-up (days)   No. of subjects^[a](#tfn1-etm-0-0-8633){ref-type="table-fn"}^   (Refs.)
  --------------------- ---------------------- -------------- ------------------ ------------- --------------------------- -------------------------- ----------------- ----------------------- --------------------------------------------------------------- -----------------------
  Sauerbruch (2015)     TIPS                   90             55                 31            NA                          45% A                      6.9               906                     27/NA/11/NA/NA                                                  ([@b20-etm-0-0-8633])
                        Propranolol+ISMN       95             55                 34            NA                          49% A                      7                 906                     25/NA/9/NA/NA                                                    
  Luo (2015)            TIPS                   37             51                 49            NA                          0/25/12                    8.76              690                     12/1/9/NA/0                                                     ([@b21-etm-0-0-8633])
                        EVL+Propranolol        36             50                 33            NA                          0/24/12                    8.89              637                     17/3/10/NA/2                                                     
  Kumar (2015)          EVL                    56             44                 NA            NA                          NA                         8.6               500                     9/NA/NA/NA/NA                                                   ([@b22-etm-0-0-8633])
                        Propranolol+ISMN       39             44                 NA            NA                          NA                         8.6               500                     8/NA/NA/NA/NA                                                    
  Kong (2015)           EVL                    20             54                 30            F2:10; F3:10                9/11/0                     NA                488                     0/NA/NA/NA/NA                                                   ([@b23-etm-0-0-8633])
                        ES                     18             53                 50            F2:9; F3:11                 8/10/0                     NA                488                     0/NA/NA/NA/NA                                                    
  Kumar (2009)          EVL+Propranolol+ISMN   88             42                 15            MG 3.1:88                   35/31/10                   3.2               458                     2/NA/NA/NA/NA                                                   ([@b24-etm-0-0-8633])
                        EVL                    89             41                 12            MG 3.2:89                   26/34/15                   3.2               458                     3/NA/NA/NA/NA                                                    
  Sauer (2002)          TIPS                   43             54                 37            MG 2.4:43                   15/16/12                   7.9               1,498                   8/1/4/1/NA                                                      ([@b25-etm-0-0-8633])
                        EVL                    42             55                 45            MG 2.6:42                   10/19/13                   8.2               1,315                   7/2/2/5/NA                                                       
  Gülberg (2002)        TIPS                   28             57                 29            NA                          11/15/2                    NA                730                     4/1/2/NA/NA                                                     ([@b26-etm-0-0-8633])
                        EVL                    26             56                 27            NA                          10/12/4                    NA                730                     4/2/1/NA/NA                                                      
  Escorsell (2002)      Propranolol+ISMN       46             56                 20            NA                          0/28/16                    NA                470                     11/4/2/NA/NA                                                    ([@b27-etm-0-0-8633])
                        TIPS                   47             57                 30            NA                          0/30/17                    NA                436                     13/3/5/NA/NA                                                     
  Villanueva (2001)     EVL                    72             58                 35            G1: 1; G2:49; G3:22         11/43/18                   8.4               666                     30/10/12/23/7                                                   ([@b28-etm-0-0-8633])
                        Nadolol+ISMN           72             60                 40            G1: 2; G2:41; G3:29         19/39/14                   7.9               605                     23/4/10/12/0                                                     
  Pomier-Layrargues     EVL                    39             54                 31            NA                          NA                         9.8               581                     16/3/9/NA/NA                                                    ([@b29-etm-0-0-8633])
  \(2001\)              TIPS                   41             53                 29            NA                          NA                         9.6               678                     17/0/10/NA/NA                                                    
  Narahara (2001)       TIPS                   38             51                 16            NA                          NA                         6.8               1,116                   11/NA/7/NA/0                                                    ([@b30-etm-0-0-8633])
                        ES                     40             55                 25            NA                          NA                         7.4               1,047                   7/NA/NA/NA/NA                                                    
  Hou (2001)            EVL                    47             55                 34            NA                          14/17/16                   8.2               351                     6/NA/4/NA/NA                                                    ([@b31-etm-0-0-8633])
                        EVL+ES                 47             59                 23            NA                          11/23/13                   8                 336                     7/NA/5/NA/NA                                                     
  Meddi (1999)          TIPS                   18             61                 28            NA                          NA                         7.6               545                     4/NA/NA/NA/NA                                                   ([@b32-etm-0-0-8633])
                        ES                     20             58                 30            NA                          NA                         7.6               545                     2/NA/NA/NA/NA                                                    
  Villarreal (1999)     TIPS                   22             58                 32            NA                          5/10/7                     8.6               760                     3/0/1/0/NA                                                      ([@b33-etm-0-0-8633])
                        ES                     24             55                 8             NA                          3/14/7                     8.8               503                     8/6/1/7/NA                                                       
  Sauer (1997)          TIPS                   42             54                 64            NA                          15/18/9                    7                 530                     12/0/7/NA/0                                                     ([@b34-etm-0-0-8633])
                        ES                     41             60                 51            NA                          12/18/11                   7                 584                     11/5/3/NA/3                                                      
  Sanyal (1997)         TIPS                   41             NA                 NA            NA                          NA                         NA                1,000                   12/NA/2/NA/NA                                                   ([@b35-etm-0-0-8633])
                        ES                     39             NA                 NA            NA                          NA                         NA                1,000                   7/NA/2/NA/NA                                                     
  Villanueva (1996)     Nadolol+ISMN           43             58                 33            G1:3; G2:30; G3:10          9/27/7                     NA                545                     4/0/2/3/1                                                       ([@b36-etm-0-0-8633])
                        ES                     43             60                 33            G1:2; G2:31; G3:10          11/22/10                   NA                545                     9/2/5/16/7                                                       
  Li (2010)             ES                     36             54                 58            G1:0; G2:0; G3:36           NA                         7.36              181.5                   7/NA/NA/4/7                                                     ([@b37-etm-0-0-8633])
                        EVL                    27             51                 26            G1: 0; G2:0; G3:27          NA                         6.86              181.5                   1/NA/NA/0/0                                                      
  Holster (2016)        EVL+Propranolol        35             54                 49            NA                          13/18/4                    7.3               708                     9/NA/0/12/2                                                     ([@b38-etm-0-0-8633])
                        TIPS                   37             56                 34            NA                          13/19/5                    7.5               708                     12/NA/3/14/1                                                     
  van Buuren (2000)     TIPS                   19             NA                 NA            NA                          NA                         NA                632                     NA/NA/NA/1/NA                                                   ([@b39-etm-0-0-8633])
                        EVL                    18             NA                 NA            NA                          NA                         NA                632                     NA/NA/NA/0/NA                                                    
  Cabrera (1996)        ES                     32             56                 28            NA                          14/16/2                    7.22              454                     5/3/NA/10/5                                                     ([@b40-etm-0-0-8633])
                        TIPS                   31             56                 35            NA                          14/13/4                    7.1               454                     6/0/NA/0/0                                                       
  Dobrucali (1998)      EVL                    50             55                 22            G2:1; G3:5; G4:44           18/23/9                    NA                908                     NA/NA/4/NA/NA                                                   ([@b41-etm-0-0-8633])
                        ES                     28             42                 43            G2:2; G3:3; G4:23           7/13/8                     NA                908                     NA/NA/0/NA/NA                                                    
  Holster (2013)        TIPS                   35             54                 44            NA                          NA                         7.4               545                     8/NA/NA/NA/NA                                                   ([@b42-etm-0-0-8633])
                        EVL                    36             54                 44            NA                          NA                         7.4               545                     7/NA/NA/NA/NA                                                    
  Merli (1994)          TIPS                   21             NA                 NA            NA                          NA                         NA                NA                      2/NA/NA/NA/NA                                                   ([@b43-etm-0-0-8633])
                        ES                     17             NA                 NA            NA                          NA                         NA                NA                      1/NA/NA/NA/NA                                                    
  Ahmad (2009)          Propranolol+ISMN       35             52                 40            G1+G2:12; G3:23             2/19/14                    9.11              182                     6/4/4/9/0                                                       ([@b44-etm-0-0-8633])
                        EVL                    39             53                 36            G1+G2:15; G3:24             7/23/9                     8.28              182                     8/2/3/12/3                                                       
                        EVL+propranolol+ISMN   37             50                 19            G1+G2:15; G3:22             4/27/6                     8.32              182                     7/2/3/8/2                                                        
  Argonz (2000)         EVL                    41             53                 22            G2:27; G3:14                14/23/4                    NA                337                     16/9/1//1                                                       ([@b45-etm-0-0-8633])
                        EVL+ES                 39             53                 23            G2:22; G3:17                11/26/2                    NA                386                     12/4/3//2                                                        
  Avgerinos (1997)      EVL                    37             55                 16            S:1; M:19; L:17             23/11/3                    7.7               472                     8/0/NA/5/2                                                      ([@b46-etm-0-0-8633])
                        ES                     40             56                 20            S:3; M:19; L:18             27/10/3                    8                 454                     8/2/NA/4/4                                                       
  Avgerinos (2004)      ES                     25             52                 24            G1:3; G2:13; G3:9           6/8/11                     9.4               42                      7/4/NA/13/NA                                                    ([@b47-etm-0-0-8633])
                        EVL                    25             56                 20            G1:3; G2:12; G3:10          7/6/12                     9.2               42                      5/2/NA/6/NA                                                      
  Avgerinos (1993)      ES                     40             59                 20            S:3; M:19; L:18             30/8/2                     7.3               1,004                   9/2/3/NA/NA                                                     ([@b48-etm-0-0-8633])
                        ES+Propranolol         45             58                 36            S:4; M:19; L:22             33/8/4                     7.6               1,035                   8/3/3/NA/NA                                                      
  Baroncini (1997)      ES                     54             61                 31            F3:36; F2:18                18/22/14                   8                 534                     12/3/NA/NA/NA                                                   ([@b49-etm-0-0-8633])
                        EVL                    57             63                 33            F3:42; F2:15                17/24/16                   7.7               496                     12/1/NA/NA/NA                                                    
  Chen (2016)           EVL                    48             56                 33            G1:18; G2:26; G3:4          19/29/0                    NA                182                     1/1/NA/0/NA                                                     ([@b16-etm-0-0-8633])
                        EVL+ES                 48             54                 35            G1:19; G2:23; G3:6          20/28/0                    NA                182                     3/2/NA/0/NA                                                      
  García-Pagán (2009)   Nadolol+ISMN           78             56                 32            L:73                        18/42/18                   8.1               454                     15/8/1/22/0                                                     ([@b50-etm-0-0-8633])
                        EVL+Nadolol+ISMN       80             57                 19            L:73                        16/46/18                   8.2               454                     16/5/4/17/4                                                      
  Hou (1995)            ES                     67             61                 21            F3:49; F2+F1:18             15/29/23                   8.2               293                     11/4/6/NA                                                       ([@b51-etm-0-0-8633])
                        EVL                    67             60                 19            F3:55; F2+F1:12             17/21/29                   8.8               287                     14/0/13/NA/NA                                                    
  Hou (2000)            ES                     70             60                 19            F3:51; F2+F1:19             17/34/19                   8                 1,918                   11/4/NA/NA/2                                                    ([@b52-etm-0-0-8633])
                        EVL                    71             60                 21            F3:57; F2+F1:14             20/26/25                   8.4               1,818                   9/1/NA/NA/3                                                      
  Lo (1995)             ES                     59             54                 17            NA                          7/24/28                    8.9               290                     19/9/6/NA/NA                                                    ([@b53-etm-0-0-8633])
                        EVL                    61             57                 21            NA                          9/22/30                    9.5               310                     10/4/6/NA/NA                                                     
  Lo (1997)             EVL                    37             53                 14            F3:27; F2:10                2/13/22                    NA                30                      7/3/3/NA/NA                                                     ([@b54-etm-0-0-8633])
                        ES                     34             55                 12            F3:26; F2:8                 3/11/20                    NA                30                      12/6/3/NA/NA                                                     
  de la Peña (2005)     EVL+Nadolol            43             60                 23            G1:10; G2:26; G3:7          6/20/11                    NA                529                     5/0/2/2/1                                                       ([@b55-etm-0-0-8633])
                        EVL                    37             60                 27            G1:7; G2:17; G3:13          6/25/12                    NA                454                     4/1/2/7/3                                                        
  Peña (1999)           ES                     46             59                 35            G1:10; G2:31; G3:5          12/22/13                   NA                545                     10/NA/3/11/2                                                    ([@b56-etm-0-0-8633])
                        EVL                    42             59                 19            G1:6; G2:25; G3:11          10/22/10                   NA                484                     8/NA/2/5/3                                                       
  Romero (2006)         Nadolol+ISMN           57             51                 35            NA                          40/44/16                   7                 348                     11/9/NA/18/0                                                    ([@b57-etm-0-0-8633])
                        EVL                    52             53                 33            NA                          32/58/10                   7                 363                     10/6/NA/12/3                                                     
  Stiegmann (1992)      ES                     65             53                 22            G1:9; G2:31; G3:25          20/32/11                   9.9               303                     29/8/NA/NA/NA                                                   ([@b58-etm-0-0-8633])
                        EVL                    64             51                 17            G1:8; G2:35; G3:21          22/30/12                   9.4               303                     18/3/NA/NA/NA                                                    
  Umehara (1999)        EVL+ES                 25             58                 NA            F3:9; F2:16                 10/11/4                    NA                611                     3/0/NA/NA/NA                                                    ([@b59-etm-0-0-8633])
                        EVL                    26             59                 NA            F3:8; F2:18                 7/13/6                     NA                629                     4/0/NA/NA/NA                                                     
  Viazis (2002)         EVL                    36             64                 42            S:9; M:17; L:10             4/18/14                    NA                50                      NA/NA/NA/NA/NA                                                  ([@b60-etm-0-0-8633])
                        ES                     37             62                 46            S:10; M:15; L:12            6/16/15                    NA                59                      NA/NA/NA/NA/NA                                                   
  Vinel (1992)          ES                     35             57                 43            F3:30; F2:5                 NA                         9.1               92                      5/3/NA/NA/NA                                                    ([@b61-etm-0-0-8633])
                        ES+Propranolol         39             55                 23            F3:20; F2:19                NA                         9.2               102                     5/4/NA/NA/NA                                                     

G, Grade; Grade 1, visible only during 1 phase of respiration or on performance of valsalva maneuver; Grade 2, visible during both phases of respiration; Grade 3, 3-6 mm; Grade 4, \>6 mm; S, small: Varix is flush with the wall of the oesphagus; M, medium: Protrusion of varix no further than halfway to the center; L, large: protrusion more than half-way to the center of the lumen; F, varicies; F1, straight, small-caliber varices; F2, moderately enlarged, beady varices; F3, markedly enlarged, nodular or tumor-shaped varices.

^a^Number of subjects for overall mortality, mortality due to rebleeding, mortality due to liver failure and treatment failure, respectively. TIPS, transjugular intrahepatic portosystemic shunt; ES, endoscopic injection sclerotherapy; EVL, endoscopic variceal ligation; ISMN, isosorbide mononitrate; MG, mean grade; NA, not available.

###### 

Ranking for efficacy of 11 potential treatment options.

       Overall mortality   Mortality due to rebleeding   Mortality due to liver failure   Treatment failure      Bleeding from gastroesophageal ulcer                                                                   
  ---- ------------------- ----------------------------- -------------------------------- ---------------------- -------------------------------------- ---------------------- -------- ---------------------- -------- ----------------------
  1    0.8162              Nadolol+ISMN                  0.8276                           TIPS alone             0.7536                                 Nadolol+ISMN           0.8071   EVL+propranolol        0.7536   Nadolol+ISMN
  2    0.7135              EVL+nadolol+ISMN              0.7265                           EVL+nadolol            0.6964                                 ES alone               0.7938   TIPS alone             0.6964   ES alone
  3    0.5983              ES+EVL                        0.6931                           EVL+nadolol+ISMN       0.6651                                 ES+propranolol         0.7932   EVL+nadolol            0.6651   ES+propranolol
  4    0.5887              EVL alone                     0.6833                           Propranolol+ISMN       0.6044                                 EVL+propranolol+ISMN   0.5630   EVL+nadolol+ISMN       0.6044   EVL+propranolol+ISMN
  5    0.5843              EVL+propranolol+ISMN          0.6047                           ES+EVL                 0.5755                                 EVL+nadolol            0.5189   ES+EVL                 0.5755   EVL+nadolol
  6    0.5218              ES+propranolol                0.5041                           Nadolol+ISMN           0.5230                                 EVL alone              0.4520   EVL+propranolol+ISMN   0.5230   EVL alone
  7    0.4847              EVL+nadolol                   0.4377                           EVL+propranolol        0.5226                                 Propranolol+ISMN       0.4328   Nadolol+ISMN           0.5226   Propranolol+ISMN
  8    0.4744              Propranolol+ISMN              0.4331                           EVL+propranolol+ISMN   0.3439                                 EVL+propranolol        0.3680   Propranolol+ISMN       0.3439   EVL+propranolol
  9    0.2811              ES alone                      0.3934                           EVL alone              0.3022                                 TIPS alone             0.2513   EVL alone              0.3022   TIPS alone
  10   0.2624              TIPS alone                    0.1125                           ES alone               0.2966                                 ES+EVL                 0.0199   ES alone               0.2966   ES+EVL
  11   0.1747              EVL+propranolol               0.0842                           ES+propranolol         0.2167                                 EVL+nadolol+ISMN                                       0.2167   EVL+nadolol+ISMN

Ranking indicates the probability to be the best treatment. Rank 1 with the highest P-score is the best treatment and rank N with the lowest P-score is the worst one. TIPS, transjugular intrahepatic portosystemic shunt; ES, endoscopic sclerotherapy; EVL, endoscopic variceal ligation; ISMN, isosorbide-5-mononitrate.

###### 

Network meta-analysis results of pairwise comparisons (Odds ratios with 95% CI).

  A, Overall mortality (Heterogeneity I^2^=0%, P=0.9618), fixed-effects model                                                                                                                                                                                                                                                             
  ------------------------------------------------------------------------------------------------ --------------------- --------------------- --------------------- ---------------------- ----------------------- ---------------------- ---------------------- ----------------------- ----------------------- ----------------------- ----------------------
  ES alone                                                                                         \-                    1.29 \[0.79,2.10\]    1.21 \[0.61,2.40\]    1.25 \[1.01,1.54\]     1.16 \[0.33,4.07\]      1.53 \[0.72,3.23\]     0.85 \[0.50,1.45\]     1.30 \[0.60,2.83\]      1.59 \[1.06,2.38\]      1.14 \[0.77,1.71\]      0.98 \[0.74,1.29\]
  ES+EVL                                                                                           0.78 \[0.48,1.27\]    \-                    0.94 \[0.40,2.18\]    0.97 \[0.62,1.52\]     0.90 \[0.24,3.36\]      1.18 \[0.50,2.78\]     0.66 \[0.33,1.32\]     1.01 \[0.42,2.43\]      1.23 \[0.69,2.19\]      0.89 \[0.49,1.60\]      0.76 \[0.45,1.28\]
  ES+propranolol                                                                                   0.83 \[0.42,1.64\]    1.06 \[0.46,2.47\]    \-                    1.03 \[0.50,2.11\]     0.96 \[0.23,4.01\]      1.26 \[0.46,3.48\]     0.70 \[0.30,1.68\]     1.08 \[0.38,3.03\]      1.31 \[0.59,2.90\]      0.95 \[0.43,2.09\]      0.81 \[0.39,1.70\]
  EVL alone                                                                                        0.80 \[0.65,0.99\]    1.03 \[0.66,1.63\]    0.97 \[0.47,1.99\]    \-                     0.93 \[0.27,3.21\]      1.22 \[0.59,2.53\]     0.68 \[0.40,1.16\]     1.05 \[0.49,2.22\]      1.27 \[0.89,1.82\]      0.92 \[0.63,1.35\]      0.79 \[0.60,1.03\]
  EVL+nadolol                                                                                      0.86 \[0.25,3.03\]    1.11 \[0.30,4.16\]    1.04 \[0.25,4.37\]    1.08 \[0.31,3.71\]     \-                      1.32 \[0.31,5.54\]     0.74 \[0.19,2.83\]     1.12 \[0.26,4.79\]      1.37 \[0.38,4.98\]      0.99 \[0.27,3.61\]      0.85 \[0.24,3.01\]
  EVL+nadolol+ISMN                                                                                 0.66 \[0.31,1.39\]    0.84 \[0.36,1.99\]    0.79 \[0.29,2.19\]    0.82 \[0.40,1.69\]     0.76 \[0.18,3.19\]      \-                     0.56 \[0.23,1.37\]     0.85 \[0.30,2.43\]      1.04 \[0.55,1.96\]      0.75 \[0.33,1.70\]      0.64 \[0.30,1.39\]
  EVL+propranolol                                                                                  1.17 \[0.69,2.00\]    1.51 \[0.76,3.02\]    1.42 \[0.60,3.38\]    1.46 \[0.86,2.48\]     1.36 \[0.35,5.23\]      1.79 \[0.73,4.39\]     \-                     1.53 \[0.62,3.76\]      1.86 \[0.99,3.52\]      1.34 \[0.76,2.36\]      1.15 \[0.73,1.81\]
  EVL+propranolol+ISMN                                                                             0.77 \[0.35,1.67\]    0.99 \[0.41,2.38\]    0.93 \[0.33,2.61\]    0.96 \[0.45,2.03\]     0.89 \[0.21,3.79\]      1.17 \[0.41,3.33\]     0.65 \[0.27,1.61\]     \-                      1.22 \[0.53,2.80\]      0.88 \[0.40,1.92\]      0.75 \[0.35,1.64\]
  Nadolol+ISMN                                                                                     0.63 \[0.42,0.94\]    0.81 \[0.46,1.44\]    0.76 \[0.34,1.69\]    0.79 \[0.55,1.12\]     0.73 \[0.20,2.65\]      0.96 \[0.51,1.81\]     0.54 \[0.28,1.01\]     0.82 \[0.36,1.89\]      \-                      0.72 \[0.43,1.21\]      0.62 \[0.40,0.96\]
  Propranolol+ISMN                                                                                 \[0.59,1.31\] 0.87    1.13 \[0.62,2.03\]    1.06 \[0.48,2.34\]    1.09 \[0.74,1.60\]     1.01 \[0.28,3.71\]      1.33 \[0.59,3.03\]     0.74 \[0.42,1.31\]     1.14 \[0.52,2.49\]      1.39 \[0.82,2.34\]      \-                      0.86 \[0.61,1.20\]
  TIPS alone                                                                                       1.02 \[0.77,1.35\]    1.31 \[0.78,2.22\]    1.23 \[0.59,2.58\]    1.27 \[0.97,1.67\]     1.18 \[0.33,4.20\]      1.56 \[0.72,3.37\]     0.87 \[0.55,1.37\]     1.33 \[0.61,2.89\]      1.62 \[1.04,2.52\]      1.17 \[0.83,1.63\]      \-
  B, Mortaility due to rebleeding (Heterogeneity I^2^=0%, P=0.9963), fixed-effects model                                                                                                                                                                                                                                                  
  Group                                                                                            ES alone              ES+EVL                ES+propranolol        EVL alone              EVL+nadolol             EVL+nadolol+ISMN       EVL+propranolol        EVL+Propranolol+ISMN    Nadolol+ISMN            Propranolol+ISMN        TIPS alone
  ES alone                                                                                         \-                    4.39                  0.80                  2.74                   9.53                    5.68                   2.70                   2.74                    3.46                    5.75                    8.31
  ES alone                                                                                         \-                    4.39 \[1.45,13.26\]   0.80 \[0.27,2.41\]    2.74 \[1.59,4.73\]     9.53 \[0.38,237.86\]    5.68 \[1.42,22.68\]    2.70 \[0.23,31.58\]    2.74 \[0.42,17.81\]     3.46 \[1.44,8.31\]      5.75 \[1.30,25.47\]     8.31 \[2.85,24.22\]
  ES+EVL                                                                                           0.23 \[0.08,0.69\]    \-                    0.18 \[0.04,0.87\]    0.62 \[0.24,1.63\]     2.17 \[0.08,59.65\]     1.29 \[0.26,6.44\]     0.61 \[0.04,8.50\]     0.62 \[0.08,4.83\]      0.79 \[0.24,2.60\]      1.31 \[0.23,7.41\]      1.89 \[0.46,7.77\]
  ES+propranolol                                                                                   1.25 \[0.42,3.76\]    5.49 \[1.15,26.14\]   \-                    3.42 \[1.00,11.71\]    11.91 \[0.40,357.18\]   7.10 \[1.21,41.67\]    3.37 \[0.23,49.96\]    3.42 \[0.39,30.05\]     4.33 \[1.06,17.67\]     7.19 \[1.13,45.80\]     10.39 \[2.24,48.26\]
  EVL alone                                                                                        0.37 \[0.21,0.63\]    1.60 \[0.61,4.19\]    0.29 \[0.09,1.00\]    \-                     3.48 \[0.15,82.91\]     2.07 \[0.57,7.50\]     0.98 \[0.09,11.36\]    1.00 \[0.16,6.09\]      1.26 \[0.62,2.57\]      2.10 \[0.50,8.88\]      3.04 \[1.08,8.54\]
  EVL+nadolol                                                                                      0.10 \[0.00,2.62\]    0.46 \[0.02,12.66\]   0.08 \[0.00,2.52\]    0.29 \[0.01,6.85\]     \-                      0.60 \[0.02,18.24\]    0.28 \[0.01,15.52\]    0.29 \[0.01,11.04\]     0.36 \[0.01,9.36\]      0.60 \[0.02,19.66\]     0.87 \[0.03,24.50\]
  EVL+nadolol+ISMN                                                                                 0.18 \[0.04,0.70\]    0.77 \[0.16,3.85\]    0.14 \[0.02,0.83\]    0.48 \[0.13,1.74\]     1.68 \[0.05,51.36\]     \-                     0.47 \[0.03,7.51\]     0.48 \[0.05,4.42\]      0.61 \[0.21,1.78\]      1.01 \[0.15,6.97\]      1.46 \[0.28,7.59\]
  EVL+propranolol                                                                                  0.37 \[0.03,4.34\]    1.63 \[0.12,22.53\]   0.30 \[0.02,4.40\]    1.02 \[0.09,11.71\]    3.53 \[0.06,193.72\]    2.11 \[0.13,33.29\]    \-                     1.01 \[0.05,19.49\]     1.28 \[0.10,16.33\]     2.13 \[0.17,27.32\]     3.08 \[0.34,28.28\]
  EVL+propranolol+ISMN                                                                             0.37 \[0.06,2.38\]    1.60 \[0.21,12.42\]   0.29 \[0.03,2.57\]    1.00 \[0.16,6.10\]     3.48 \[0.09,133.93\]    2.08 \[0.23,19.05\]    0.99 \[0.05,18.94\]    \-                      1.27 \[0.18,8.80\]      2.10 \[0.29,15.46\]     3.04 \[0.43,21.47\]
  Nadolol+ISMN                                                                                     0.29 \[0.12,0.69\]    1.27 \[0.38,4.19\]    0.23 0.06,0.94\]      0.79 \[0.39,1.61\]     2.75 \[0.11,70.92\]     1.64 \[0.56,4.80\]     0.78 \[0.06,9.91\]     0.79 \[0.11,5.50\]      \-                      1.66 \[0.33,8.26\]      2.40 \[0.69,8.37\]
  Propranolol+ISMN                                                                                 0.17 \[0.04,0.77\]    0.76 \[0.13,4.31\]    0.14 \[0.02,0.89\]    0.48 \[0.11,2.01\]     1.66 \[0.05,53.91\]     0.99 \[0.14,6.79\]     0.47 \[0.04,6.00\]     0.48 \[0.06,3.49\]      0.60 \[0.12,2.99\]      \-                      1.45 \[0.41,5.10\]
  TIPS alone                                                                                       0.12 \[0.04,0.35\]    0.53 \[0.13,2.17\]    0.10 \[0.02,0.45\]    0.33 \[0.12,0.93\]     1.15 \[0.04,32.17\]     0.68 \[0.13,3.54\]     0.32 \[0.04,2.97\]     0.33 \[0.05,2.32\]      0.42 \[0.12,1.45\]      0.69 \[0.20,2.44\]      \-
  C, Mortality due to liver failure (Heterogeneity I^2^=0%, P=0.8985), fixed-effects model                                                                                                                                                                                                                                                
  Group                                                                                            ES alone              ES+EVL                ES+propranolol        EVL alone              EVL+nadolol             EVL+nadolol+ISMN       EVL+propranolol        EVL+Propranolol+ISMN    Nadolol+ISMN            Propranolol+ISMN        TIPS alone
  ES alone                                                                                         \-                    0.51 \[0.15,1.68\]    1.13 \[0.24,5.26\]    0.80 \[0.49,1.29\]     0.92 \[0.13,6.63\]      0.29 \[0.03,2.97\]     0.59 \[0.23,1.50\]     0.94 0.23,3.90\]        1.15 \[0.52,2.55\]      0.79 \[0.34,1.79\]      0.59 \[0.34,1.03\]
  ES+EVL                                                                                           1.96 \[0.60,6.46\]    \-                    2.21 \[0.31,15.51\]   1.56 \[0.53,4.65\]     1.82 \[0.20,16.37\]     0.58 \[0.05,7.24\]     1.15 \[0.28,4.78\]     1.85 \[0.32,10.65\]     2.26 \[0.62,8.24\]      1.54 \[0.41,5.87\]      1.15 \[0.35,3.86\]
  ES+propranolol                                                                                   0.89 \[0.19,4.16\]    0.45 \[0.06,3.18\]    \-                    0.71 \[0.14,3.56\]     0.82 \[0.07,10.03\]     0.26 \[0.02,4.21\]     0.52 \[0.09,3.17\]     0.84 \[0.10,6.83\]      1.02 \[0.18,5.79\]      0.70 \[0.12,4.01\]      0.52 \[0.10,2.69\]
  EVL alone                                                                                        1.26 \[0.78,2.03\]    0.64 \[0.22,1.90\]    1.41 \[0.28,7.11\]    \-                     1.16 \[0.17,7.85\]      0.37 \[0.04,3.62\]     0.74 \[0.30,1.84\]     1.19 \[0.30,4.66\]      1.44 \[0.72,2.91\]      0.99 \[0.46,2.14\]      0.74 0.44,1.24\]
  EVL+nadolol                                                                                      1.08 \[0.15,7.75\]    0.55 \[0.06,4.97\]    1.22 \[0.10,14.84\]   0.86 \[0.13,5.81\]     \-                      0.32 \[0.02,6.23\]     0.64 \[0.08,5.27\]     1.02 \[0.10,10.69\]     1.24 \[0.16,9.50\]      0.85 \[0.11,6.67\]      0.64 \[0.09,4.60\]
  EVL+nadolol+ISMN                                                                                 3.39 \[0.34,34.20\]   1.73 \[0.14,21.63\]   3.82 \[0.24,61.42\]   2.70 \[0.28,26.39\]    3.14 \[0.16,61.42\]     \-                     1.99 \[0.17,23.05\]    3.20 \[0.23,45.57\]     3.90 \[0.45,34.12\]     2.67 \[0.24,29.42\]     1.99 \[0.19,20.50\]
  EVL+propranolol                                                                                  1.70 \[0.67,4.33\]    0.87 \[0.21,3.59\]    1.91 \[0.32,11.62\]   1.35 \[0.54,3.37\]     1.57 \[0.19,13.06\]     0.50 \[0.04,5.80\]     \-                     1.61 \[0.33,7.70\]      1.96 \[0.63,6.08\]      1.34 \[0.49,3.64\]      1.00 \[0.47,2.12\]
  EVL+propranolol+ISMN                                                                             1.06 \[0.26,4.39\]    0.54 \[0.09,3.11\]    1.19 \[0.15,9.71\]    0.84 \[0.21,3.32\]     0.98 \[0.09,10.28\]     0.31 \[0.02,4.45\]     0.62 \[0.13,2.99\]     \-                      1.22 \[0.26,5.64\]      0.83 \[0.22,3.16\]      0.62 \[0.16,2.47\]
  Nadolol+ISMN                                                                                     0.87 \[0.39,1.93\]    0.44 \[0.12,1.62\]    0.98 \[0.17,5.55\]    0.69 \[0.34,1.40\]     0.80 \[0.11,6.16\]      0.26 \[0.03,2.24\]     0.51 \[0.16,1.59\]     0.82 \[0.18,3.80\]      \-                      0.68 \[0.24,1.91\]      0.51 \[0.22,1.20\]
  Propranolol+ISMN                                                                                 1.27 \[0.56,2.90\]    0.65 \[0.17,2.47\]    1.43 \[0.25,8.23\]    1.01 \[0.47,2.19\]     1.18 \[0.15,9.24\]      0.38 \[0.03,4.14\]     0.75 \[0.27,2.04\]     1.20 \[0.32,4.55\]      1.46 \[0.52,4.09\]      \-                      0.75 \[0.39,1.45\]
  TIPS alone                                                                                       1.70 \[0.97,2.97\]    0.87 \[0.26,2.90\]    1.91 \[0.37,9.87\]    1.35 \[0.81,2.28\]     1.57 \[0.22,11.39\]     0.50 \[0.05,5.15\]     1.00 \[0.47,2.11\]     1.61 \[0.41,6.36\]      1.95 \[0.83,4.58\]      1.34 \[0.69,2.60\]      \-
  D, Treatment failure (Heterogeneity I^2^=29.4%, P=0.1739), fixed-effects model                                                                                                                                                                                                                                                          
  Group                                                                                            ES alone              ES+EVL                EVL alone             EVL+nadolol            EVL+nadolol+ISMN        EVL+propranolol        EVL+Propranolol+ISMN   Nadolol+ISMN            Propranolol+ISMN        TIPS alone              
  ES alone                                                                                         \-                    3.72 \[1.30,10.67\]   2.13 \[1.31,3.45\]    8.65 \[1.77,42.15\]    3.69 \[1.65,8.27\]      9.09 \[2.08,39.68\]    3.02 \[1.22,7.53\]     2.78 \[1.54,5.02\]      2.54 \[1.06,6.12\]      8.24 \[2.16,31.40\]     
  ES+EVL                                                                                           0.27 \[0.09,0.77\]    \-                    0.57 \[0.22,1.48\]    2.32 \[0.39,13.82\]    0.99 \[0.31,3.21\]      2.44 \[0.43,13.94\]    0.81 \[0.24,2.77\]     0.75 \[0.27,2.11\]      0.68 \[0.21,2.27\]      2.21 \[0.43,11.29\]     
  EVL alone                                                                                        0.47 \[0.29,0.76\]    1.75 \[0.68,4.53\]    \-                    4.07 \[0.90,18.39\]    1.74 \[0.87,3.46\]      4.28 \[0.99,18.49\]    1.42 \[0.66,3.08\]     1.31 \[0.86,1.98\]      1.20 \[0.57,2.49\]      3.88 \[1.03,14.61\]     
  EVL+nadolol                                                                                      0.12                  0.43                  0.25                  \-                     0.43                    1.05                   0.35                   0.32                    0.29                    0.95                    
  EVL+nadolol                                                                                      0.12 \[0.02,0.56\]    0.43 \[0.07,2.56\]    0.25 \[0.05,1.11\]    \-                     0.43 \[0.08,2.24\]      1.05 \[0.13,8.61\]     0.35 \[0.06,1.91\]     0.32 \[0.07,1.54\]      0.29 \[0.05,1.58\]      0.95 \[0.13,7.11\]      
  EVL+nadolol+ISMN                                                                                 0.27 \[0.12,0.61\]    1.01 \[0.31,3.26\]    0.58 \[0.29,1.15\]    2.34 \[0.45,12.30\]    \-                      2.46 \[0.49,12.31\]    0.82 \[0.29,2.31\]     0.75 \[0.43,1.31\]      0.69 \[0.25,1.89\]      2.23 \[0.50,9.87\]      
  EVL+propranolol                                                                                  0.11 \[0.03,0.48\]    0.41 \[0.07,2.34\]    0.23 \[0.05,1.01\]    0.95 \[0.12,7.78\]     0.41 \[0.08,2.03\]      \-                     0.33 \[0.06,1.74\]     0.31 \[0.07,1.39\]      0.28 \[0.05,1.44\]      0.91 \[0.49,1.68\]      
  EVL+propranolol+ISMN                                                                             0.33 \[0.13,0.82\]    1.23 \[0.36,4.19\]    0.70 \[0.32,1.52\]    2.86 \[0.52,15.57\]    1.22 \[0.43,3.44\]      3.01 \[0.57,15.74\]    \-                     0.92 \[0.38,2.21\]      0.84 \[0.37,1.93\]      2.72 \[0.59,12.65\]     
  Nadolol+ISMN                                                                                     0.36 \[0.20,0.65\]    1.34 \[0.47,3.77\]    0.76 \[0.50,1.16\]    3.11 \[0.65,14.86\]    1.33 \[0.77,2.30\]      3.27 \[0.72,14.83\]    1.09 \[0.45,2.61\]     \-                      0.91 \[0.39,2.12\]      2.96 \[0.74,11.78\]     
  Propranolol+ISMN                                                                                 0.39 \[0.16,0.95\]    1.46 \[0.44,4.86\]    0.84 \[0.40,1.74\]    3.40 \[0.63,18.20\]    1.45 \[0.53,3.98\]      3.57 \[0.70,18.38\]    1.19 \[0.52,2.73\]     1.09 \[0.47,2.54\]      \-                      3.24 \[0.71,14.76\]     
  TIPS alone                                                                                       0.12 \[0.03,0.46\]    0.45 \[0.09,2.30\]    0.26 \[0.07,0.97\]    1.05 \[0.14,7.83\]     0.45 \[0.10,1.98\]      1.10 \[0.60,2.05\]     0.37 \[0.08,1.71\]     0.34 \[0.08,1.34\]      0.31 \[0.07,1.41\]      \-                      
  E, Bleeding from gastroesophageal ulcer (Heterogeneity I^2^=0%, P=0.8354), fixed-effects model                                                                                                                                                                                                                                          
  Group                                                                                            ES alone              ES+EVL                EVL alone             EVL+nadolol            EVL+nadolol+ISMN        EVL+propranolol        EVL+Propranolol+ISMN   Nadolol+ISMN            Propranolol+ISMN        TIPS alone              
  ES alone                                                                                         \-                    0.55 \[0.04,6.88\]    1.16 \[0.48,2.82\]    4.05 \[0.37,44.27\]    1.07 \[0.04,28.38\]     2.71 \[0.22,32.94\]    1.64 \[0.24,11.51\]    9.41 \[2.07,42.79\]     7.51 \[0.35,160.14\]    8.02 \[1.50,42.92\]     
  ES+EVL                                                                                           1.81 \[0.15,22.50\]   \-                    2.10 \[0.20,22.27\]   \[0.29,187.21\]        1.94 \[0.03,109.86\]    4.89 \[0.14,170.35\]   2.97 \[0.16,55.53\]    17.01 \[1.03,280.81\]   13.58 \[0.32,583.96\]   14.51 \[0.70,299.70\]   
  EVL alone                                                                                        0.86 \[0.35,2.09\]    0.48 \[0.04,5.04\]    \-                    3.49 \[0.38,32.10\]    0.92 \[0.03,24.40\]     2.33 \[0.16,33.00\]    1.41 \[0.25,7.99\]     8.09 \[1.78,36.77\]     6.46 \[0.35,120.78\]    6.90 \[1.04,46.00\]     
  EVL+nadolol                                                                                      0.25 \[0.02,2.69\]    0.14 \[0.01,3.48\]    0.29 \[0.03,2.64\]    \-                     0.26 \[0.01,13.83\]     0.67 \[0.02,21.21\]    0.41 \[0.02,6.78\]     2.32 \[0.16,34.08\]     1.85 \[0.05,73.08\]     1.98 \[0.11,36.71\]     
  EVL+nadolol+ISMN                                                                                 0.93 \[0.04,24.71\]   0.52 \[0.01,29.25\]   1.09 \[0.04,28.72\]   3.78 \[0.07,197.91\]   \-                      2.52 \[0.04,155.57\]   1.53 \[0.04,62.41\]    8.78 \[0.48,160.33\]    7.01 \[0.09,567.49\]    7.49 \[0.19,297.05\]    
  EVL+propranolol                                                                                  0.37 \[0.03,4.50\]    0.20 \[0.01,7.11\]    0.43 \[0.03,6.09\]    1.50 \[0.05,47.60\]    0.40 \[0.01,24.40\]     \-                     0.61 \[0.03,14.43\]    3.48 \[0.19,64.62\]     2.78 \[0.05,144.26\]    2.97 \[0.46,18.92\]     
  EVL+propranolol+ISMN                                                                             0.61 \[0.09,4.26\]    0.34 \[0.02,6.28\]    0.71 \[0.13,4.00\]    2.47 \[0.15,41.18\]    0.65 \[0.02,26.51\]     1.65 \[0.07,39.07\]    \-                     5.72 \[0.57,57.07\]     4.57 \[0.23,91.89\]     4.88 \[0.37,63.66\]     
  Nadolol+ISMN                                                                                     0.11 \[0.02,0.48\]    0.06 \[0.00,0.97\]    0.12 \[0.03,0.56\]    0.43 \[0.03,6.33\]     0.11 \[0.01,2.08\]      0.29 \[0.02,5.35\]     0.17 \[0.02,1.74\]     \-                      0.80 \[0.03,21.58\]     0.85 \[0.09,8.18\]      
  Propranolol+ISMN                                                                                 0.13 \[0.01,2.84\]    0.07 \[0.00,3.17\]    0.15 \[0.01,2.89\]    0.54 \[0.01,21.28\]    0.14 \[0.00,11.55\]     0.36 \[0.01,18.72\]    0.22 \[0.01,4.40\]     1.25 \[0.05,33.83\]     \-                      1.07 \[0.03,34.99\]     
  TIPS alone                                                                                       0.12 \[0.02,0.67\]    0.07 \[0.00,1.42\]    0.14 \[0.02,0.97\]    0.51 \[0.03,9.37\]     0.13 \[0.00,5.30\]      0.34 \[0.05,2.15\]     0.20 \[0.02,2.67\]     1.17 \[0.12,11.23\]     0.94 \[0.03,30.66\]     \-                      

TIPS, transjugular intrahepatic portosystemic shunt; ES, endoscopic sclerotherapy; EVL, endoscopic variceal ligation; ISMN, isosorbide-5-mononitrate.

###### 

Heterogeneity test results.

  Item                                       I^2^ (%)   Q       DF   P-value
  ------------------------------------------ ---------- ------- ---- ---------
  Overall mortality                          0          19.34   32   0.9618
  Overall mortality (sensitivity analysis)   0          18.05   28   0.9249
  Mortality due to rebleeding                0          5.97    18   0.9963
  Treatment failure                          29.4       12.76   9    0.1739
  Treatment failure (sensitivity analysis)   37.3       12.75   8    0.1206
  Bleeding from gastroesophageal ulcer       0          4.23    8    0.8354
  Mortality due to liver failure             0          8.58    15   0.8985

DF, degrees of freedom.

[^1]: *Abbreviations:* AASLD, American Association for the Study of Liver Diseases; ES, endoscopic sclerotherapy; EVL, endoscopic variceal ligation; ISMN, isosorbide mononitrate; NSBB, non-selective β-blockers; OR, odds ratio; RCT, randomized controlled trial; TIPS, transjugular intrahepatic portosystemic shunt
